Vedanta Biosciences said Wednesday that a mid-stage trial of its VE202 drug candidate to treat ulcerative colitis did not meet its primary endpoint of endoscopic response.
VE202 was well tolerated, with no reports of serious adverse events, said Vedanta, a PureTech Health (PRTC) founded entity.
Vedanta said it remains focused on its lead program, VE303, for the prevention of recurrent clostridioides difficile infection.
Separately, PureTech said its stake in Vedanta has been diluted to 4.2% over the course of 2025.
Price: 18.20, Change: +0.87, Percent Change: +5.02
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments